Trial · NCT06818266
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to successful weaning from both supplemental oxygen and any respiratory support | During hospitalization for ACS, from randomization until day 28 after randomization | Successful weaning from both supplemental oxygen and any respiratory support, defined as SpO2 ≥ 95% without oxygen during the next 24 hours, and spontaneous breathing without any respiratory support (non-invasive or invasive) during the next 48 hours |
| Secondary | Adverse events during hospitalization and within 3 months following tocilizumab or placebo injection | Within 3 months after randomization | Severe and not severe adverse events (including hypertension, hypersensitivity reactions, hypokalemia, neutropenia, thrombocytopenia, infections, pulmonary embolism/thrombosis, hepatic cytolysis, organ failure) |
| Secondary | Time to discharge | From the date of randomization until the date of end of hospitalization, assessed up to 3 months | Length of hospital stay |
| Secondary | Mortality | Within 3 months after randomization | Mortality |
| Secondary | Need for transfusion | From the date of randomization until the date of end of hospitalization, assessed up to 3 months | Need for red blood cell transfusion |
| Secondary | Total number of red blood cell units received | From the date of randomization until the date of end of hospitalization, assessed up to 3 months | Total number of red blood cell units received |
| Secondary | Need for non-invasive ventilation (for patients without ventilatory support at inclusion) | From the date of randomization until the date of end of hospitalization, assessed up to 3 months | Need for non-invasive ventilation (high flow nasal oxygen, continuous positive airway pressure, or bilevel non-invasive ventilation), for patients without ventilatory support at inclusion |
| Secondary | Need for invasive ventilation (for patients without invasive ventilation at inclusion) | From the date of randomization until the date of end of hospitalization, assessed up to 3 months | Need for invasive ventilation, for patients without invasive ventilation at inclusion |
| Secondary | Readmission for vaso-occlusive crisis or ACS within 3 months following tocilizumab or placebo injection | Within 3 months after randomization | Readmission for vaso-occlusive crisis or ACS within 3 months following tocilizumab or placebo injection |
| Secondary | C-reactive protein (CRP), procalcitonin (PCT), plasma and sputum IL-6 levels 48 (+/- 12) hours after tocilizumab or placebo injection | 48 (+/- 12) hours after tocilizumab or placebo injection | C-reactive protein (CRP), procalcitonin (PCT), plasma and sputum IL-6 levels 48 (+/- 12) hours after tocilizumab or placebo injection |
| Secondary | Procalcitonin (PCT) level 48 (+/- 12) hours after tocilizumab or placebo injection | 48 (+/- 12) hours after tocilizumab or placebo injection | Procalcitonin (PCT) level 48 (+/- 12) hours after tocilizumab or placebo injection |
| Secondary | Plasma IL-6 level 48 (+/- 12) hours after tocilizumab or placebo injection | 48 (+/- 12) hours after tocilizumab or placebo injection | Plasma IL-6 level 48 (+/- 12) hours after tocilizumab or placebo injection |
| Secondary | Sputum IL-6 level 48 (+/- 12) hours after tocilizumab or placebo injection | 48 (+/- 12) hours after tocilizumab or placebo injection | Sputum IL-6 level 48 (+/- 12) hours after tocilizumab or placebo injection |
| Secondary | Chest imaging improvement 48 (+/- 12) hours after tocilizumab or placebo injection | 48 (+/- 12) hours after tocilizumab or placebo injection | Improvement of chest imaging (chest X-ray or lung ultrasound) will be assessed by an investigator, who will have to choose between 3 possible answers: worsening, stability or improvement of ACS images. |
| Secondary | Tocilizumab level in the plasma 48 (+/- 12) hours after tocilizumab or placebo injection | 48 (+/- 12) hours after tocilizumab or placebo injection | Tocilizumab level in the plasma 48 (+/- 12) hours after tocilizumab or placebo injection |
| Secondary | Tocilizumab level in the sputum (or in the tracheal aspirations in case of invasive mechanical ventilation) 48 (+/- 12) hours after tocilizumab or placebo injection | 48 (+/- 12) hours after tocilizumab or placebo injection | Tocilizumab level in the sputum (or in the tracheal aspirations in case of invasive mechanical ventilation) 48 (+/- 12) hours after tocilizumab or placebo injection |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06818266/registered